Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Recruiting in Palo Alto (17 mi)

Overseen byDustin Osborne, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Tennessee

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial involves injecting tiny radioactive beads into the liver to treat liver cancer. It targets patients with liver cancer who may not respond to other treatments. The beads release radiation that kills cancer cells directly in the liver. This method has been developed as a treatment for liver tumors, delivering high levels of local radiation to the tumor site.

Eligibility Criteria

Inclusion Criteria

All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study

Must be able to schedule and tolerate additional PET/CT imaging following therapy

Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: TheraSpheres Therapy SelectionExperimental Treatment1 Intervention

Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.

Group II: SIR-Spheres Therapy SelectionExperimental Treatment1 Intervention

Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.